If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
== Single-cell isolation == Many single-cell analysis techniques require the isolation of individual cells. Methods currently used for single-cell isolation include: dielectrophoretic digital sorting, enzymatic digestion, fluorescence-activated cell sorter, hydrodynamic traps, laser capture microdissection, manual picking, microfluidics, inkjet printing, micromanipulation, serial dilution, and Raman tweezers. Manual single-cell picking is a method where cells in suspension are viewed under a microscope and individually picked using a micropipette. The Raman tweezers technique combines Raman spectroscopy with optical tweezers, using a laser beam to trap and manipulate cells. The dielectrophoretic digital sorting method utilizes a semiconductor-controlled array of electrodes in a microfluidic chip to trap single cells in dielectrophoretic (DEP) cages. Cell identification is ensured by the combination of fluorescent markers with image observation. Precision delivery is ensured by the semiconductor-controlled motion of DEP cages in the flow cell. Inkjet printing combines microfluidics with MEMS on a CMOS chip to provide individual control over a large number of print nozzles, using the same technology as home Inkjet printing. Inkjet printing allows for the adjustment of shear force to the sample ejection, greatly improving cell survivability.
== Technology == Flagler Global Logistics is using a new, proprietary, single-source, cold chain technology to attract more business from Latin and South American importers of perishable goods. Importers generally use colder northern ports, and then truck the products (which can include fruits, vegetables, and fresh-cut flowers) south in order to protect local farms against fruit flies and other pests. However, this circuitous supply chain route can contribute to large losses in products. Industry reports estimate that $35 billion in perishable foods are lost annually between farm and table, with nearly half of those losses due to in-transit temperature changes. FGL's new facility allows the company to employ a new cold chain process and treatment methods that can extend the shelf life of produce and other perishable items. In December 2013, the USDA approved the Logistics Center's treatment methods. Flagler Global Logistics President and CEO Chris Scott described the USDA approval as a “game-changer” in the industry, because it opens up Miami as a viable alternate distribution hub for Latin America exporters. Flagler Global Logistics also holds certifications from PrimusGFS (Global Food Safety Initiative scheme) and the FDA.
=== Black chuño === Black chuño is obtained directly from the original freezing, trampling, and refreezing process. The product is not washed or exposed to water again; after freezing and trampling, it is simply sun-dried. Black chuño production has less regional variation than white chuño, and is more likely to be kept and consumed by farmers than the more commercialized white chuño.
The 1988 US presidential elections lent new urgency to the negotiations, which had recently stalled after six consecutive rounds of talks in Brazzaville. Angola and Cuba had gambled heavily on a victory for Michael Dukakis and the Democratic Party during the US elections, hoping that this would spell the end of US aid to UNITA and a harder line on South Africa. At the time of the Geneva Protocol, dos Santos had commented that "if the Democrats had won the elections, there would be a readjustment in US policy, particularly on Southern Africa". The election of Republican candidate George H. W. Bush had the effect of persuading the Angolan and Cuban delegations to be more flexible. Crocker reiterated on several occasions that a new US administration meant changes in personnel and basic policy review, and pressed them not to waste months of effort. Three days after the US election results were released, the parties reconvened in Geneva and within the week had agreed to a phased Cuban withdrawal over the course of twenty seven months. In exchange, South Africa pledged to begin bestowing independence on South West Africa by 1 November 1989. On 13 December 1988, South Africa, Angola, and Cuba signed the Brazzaville Protocol, which affirmed their commitment to these conditions and set up a Joint Military Monitoring Commission (JMMC) to supervise the disengagement in Angola. The JMMC was to include Soviet and US observers. All hostilities between the belligerents, including PLAN, were to formally cease by 1 April 1989.
Sources: en.wikipedia.org
=== Video === introduction to NMR and MRI Richard Ernst, NL – Developer of multidimensional NMR techniques Freeview video provided by the Vega Science Trust. 'An Interview with Kurt Wuthrich' Freeview video by the Vega Science Trust (Wüthrich was awarded a Nobel Prize in Chemistry in 2002 "for his development of nuclear magnetic resonance spectroscopy for determining the three-dimensional structure of biological macromolecules in solution"). The Nobel Prize Winner - Documentary about Richard R. Ernst by Lukas Schwarzenbacher and Susanne Schmid (Swiss German with English subtitles) Other Qian, C.; Pines, A.; Martin, R. W. (September 2007). "Off Magic Angle Spinning". Journal of Magnetic Resonance. 188 (1): 183–189. Bibcode:2007JMagR.188..183Q. doi:10.1016/j.jmr.2007.06.006. PMID 17638585. Spotlight on nuclear magnetic resonance: a timeless technique
A steroid is an organic compound with four fused rings (designated A, B, C, and D) arranged in a specific molecular configuration. Steroids have two principal biological functions: as important components of cell membranes that alter membrane fluidity; and as signaling molecules. Examples include the lipid cholesterol, sex hormones estradiol and testosterone, anabolic steroids, and the anti-inflammatory corticosteroid drug dexamethasone. Hundreds of steroids are found in fungi, plants, and animals. All steroids are manufactured in cells from sterol precursors: cholesterol and lanosterol (in opisthokonts), or cycloartenol (in plants). All three of these molecules are produced via cyclization of the triterpene squalene.
=== Printed === Bönisch, Susanne (1996). Natural Healing for Cats. Sterling Publishing Company. ISBN 978-0-8069-8122-2. Casal, Margret; Jezyk, Peter; Giger, Urs (1996). "Transfer of Colostral Antibodies From Queens to Their Kittens". American Journal of Veterinary Research. 57 (11): 1653–1658. doi:10.2460/ajvr.1996.57.11.1653. PMID 8915447. Crowell-Davis, Sharon (2005). "Cat Behaviour: Social Organization, Communication and Development". The Welfare of Cats. Animal Welfare. Vol. 3. Rochlitz. pp. 1–22. doi:10.1007/1-4020-3227-7_1. ISBN 1-4020-3226-9. Guilford, Grant (1994). "Nutritional Management of Gastrointestinal Tract Diseases of Dogs and Cats". Journal of Nutrition. 124 (12 Suppl): 2663S–2669S. doi:10.1093/jn/124.suppl_12.2663S. PMC 7107501. PMID 7996263. Heath, Sarah (2005). "Behaviour Problems and Welfare". The Welfare of Cats. Animal Welfare. Vol. 3. Rochlitz. pp. 91–118. doi:10.1007/1-4020-3227-7_4. ISBN 1-4020-3226-9. McHattie, Grace (1993). That's Cats! A Compendium of Feline Facts. David & Charles. ISBN 978-0-7153-0126-5. Messonnier, Shawn (2010). Natural Health Bible for Dogs & Cats: Your A-Z Guide to Over 200 Conditions, Herbs, Vitamins, and Supplements. Crown/Archetype Publishing. ISBN 978-0-307-55860-2. Olson, Patricia; Kustritz, Margaret; Johnston, Shirley (2001). "Early-age Neutering of Dogs and Cats in the United States". Journal of Reproduction and Fertility Supplement. 57: 223–232. PMID 11787153. Poirier, Frank; Hussey, Kaye (1982). "Nonhuman Primate Learning: The Importance of Learning from an Evolutionary Perspective".
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.